{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:58:04Z","timestamp":1791503884940,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Breast Cancer Research Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The randomized phase 2 Neo-peaks study examined usefulness of neoadjuvant trastuzumab emtansine\u2009+\u2009pertuzumab (T-DM1\u2009+\u2009P) following docetaxel\u2009+\u2009carboplatin\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab (TCbHP) as compared with the standard TCbHP regimen. We previously reported that pCR rate after neoadjuvant therapy tended to be higher with TCbHP followed by T-DM1\u2009+\u2009P. We conducted an exploratory analysis of prognosis 5\u00a0years after surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Neoadjuvant treatment with TCbHP (6 cycles; group A), TCbHP (4 cycles) followed by T-DM1\u2009+\u2009P (4 cycles; group B), and T-DM1\u2009+\u2009P (4 cycles; group C,\u2009+\u20092 cycles in responders) were compared. Group C non-responders after 4 cycles were switched to an anthracycline-based regimen. We evaluated 5-year disease-free survival (DFS), distant DFS (DDFS), and overall survival (OS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 203 patients (50, 52, and 101 in groups A\u2013C, respectively) were analyzed. No significant intergroup differences were found for DFS, DDFS, or OS. The 5-year DFS rates (95% CI) were 91.8% (79.6\u201396.8%), 92.3% (80.8\u201397.0%), and 88.0% (79.9\u201393.0%) in groups A\u2013C, respectively. TCbHP followed by T-DM1\u2009+\u2009P and T-DM1\u2009+\u2009P with response-guided addition of anthracycline therapy resulted in similar long-term prognosis to that of TCbHP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients who achieved pCR after neoadjuvant therapy with T-DM1\u2009+\u2009P, omission of adjuvant anthracycline may be considered, whereas treatment should be adjusted for non-pCR patients with residual disease. T-DM1\u2009+\u2009P with response-guided treatment adjustment may be useful for minimizing toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number and date of registration<\/jats:title>\n                <jats:p>UMIN-CTR, UMIN000014649, prospectively registered July 25, 2014. Some of the study results were presented as a Mini Oral session at the ESMO Breast Cancer 2023 (Berlin, Germany, 11\u201313 May 2023).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-024-07333-7","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T06:01:37Z","timestamp":1716184897000},"page":"33-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term outcomes of neoadjuvant trastuzumab emtansine\u2009+\u2009pertuzumab (T-DM1\u2009+\u2009P) and docetaxel\u2009+\u2009carboplatin\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)"],"prefix":"10.1007","volume":"207","clinical-trial-number":[{"clinical-trial-number":"umin000014649","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"Toshimi","family":"Takano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-5952","authenticated-orcid":false,"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-3647","authenticated-orcid":false,"given":"Hiroko","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4349-9046","authenticated-orcid":false,"given":"Rikiya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7727-8869","authenticated-orcid":false,"given":"Kazushige","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-8972","authenticated-orcid":false,"given":"Tomoyuki","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroi","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-8976","authenticated-orcid":false,"given":"Tatsuki R.","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"2\u20133","key":"7333_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0304-419x(94)90012-4","volume":"1198","author":"NE Hynes","year":"1994","unstructured":"Hynes NE, Stern DF (1994) The biology of erbB-2\/neu\/HER-2 and its role in cancer. Biochim Biophys Acta 1198(2\u20133):165\u2013184. https:\/\/doi.org\/10.1016\/0304-419x(94)90012-4","journal-title":"Biochim Biophys Acta"},{"key":"7333_CR2","unstructured":"NCCN Guidelines: Breast Cancer. https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"issue":"3","key":"7333_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12282-020-01085-0","volume":"27","author":"T Shimoi","year":"2020","unstructured":"Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T (2020) The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer 27(3):322\u2013331. https:\/\/doi.org\/10.1007\/s12282-020-01085-0","journal-title":"Breast Cancer"},{"key":"7333_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.molonc.2009.01.003","volume":"3","author":"J Rockberg","year":"2009","unstructured":"Rockberg J, Schwenk JM, Uhl\u00e9n M (2009) Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies. Mol Oncol 3:238\u2013247. https:\/\/doi.org\/10.1016\/j.molonc.2009.01.003","journal-title":"Mol Oncol"},{"issue":"1","key":"7333_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"7333_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1186\/s12885-019-6132-0","volume":"19","author":"S Chen","year":"2019","unstructured":"Chen S, Liang Y, Feng Z, Wang M (2019) Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. BMC Cancer 19(1):973. https:\/\/doi.org\/10.1186\/s12885-019-6132-0","journal-title":"BMC Cancer"},{"issue":"1","key":"7333_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115\u2013126. https:\/\/doi.org\/10.1016\/S1470-2045(17)30716-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"7333_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-020-05524-6","volume":"180","author":"N Masuda","year":"2020","unstructured":"Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M (2020) A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat 180(1):135\u2013146. https:\/\/doi.org\/10.1007\/s10549-020-05524-6","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"7333_CR9","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796\u20131804. https:\/\/doi.org\/10.1200\/JCO.2011.38.8595","journal-title":"J Clin Oncol"},{"key":"7333_CR10","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (Japanese Clinical Oncology Group edition). https:\/\/jcog.jp\/doctor\/tool\/ctcaev4\/ Accessed 1 Aug 2023"},{"issue":"5","key":"7333_CR11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/JCO.21.00896","volume":"40","author":"IE Krop","year":"2022","unstructured":"Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N (2022) Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2\u2013positive early breast cancer: the phase III KAITLIN study. J Clin Oncol 40(5):438\u2013448. https:\/\/doi.org\/10.1200\/JCO.21.00896","journal-title":"J Clin Oncol"},{"issue":"25","key":"7333_CR12","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.19.00882","volume":"37","author":"SA Hurvitz","year":"2019","unstructured":"Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D (2019) Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2\u2013positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol 37(25):2206\u20132216. https:\/\/doi.org\/10.1200\/JCO.19.00882","journal-title":"J Clin Oncol"},{"issue":"1","key":"7333_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100772","volume":"8","author":"E De Azambuja","year":"2023","unstructured":"De Azambuja E, Agostinetto E, Procter M, Eiger D, Pond\u00e9 N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T, Steering Committee APHINITY, Investigators, (2023) Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open 8(1):100772. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100772","journal-title":"ESMO Open"},{"issue":"9","key":"7333_CR14","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cort\u00e9s J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278\u20132284. https:\/\/doi.org\/10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"key":"7333_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cort\u00e9s J (2018) Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 89:27\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.021","journal-title":"Eur J Cancer"},{"issue":"11","key":"7333_CR16","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/annonc\/mdx494Erratum.In:AnnOncol.2022;33(3):355","volume":"28","author":"UA Nitz","year":"2017","unstructured":"Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N (2017) De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+\/HR\u2013 phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab \u00b1 weekly paclitaxel. Ann Oncol 28(11):2768\u20132772. https:\/\/doi.org\/10.1093\/annonc\/mdx494Erratum.In:AnnOncol.2022;33(3):355","journal-title":"Ann Oncol"},{"issue":"5","key":"7333_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"UA Nitz","year":"2020","unstructured":"Nitz UA, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; the WSG-ADAPT Investigators, (2020) De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor\u2013negative, early breast cancer (WSG-ADAPT-HER2\/HR\u2013): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 23(5):625\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(22)00159-0","journal-title":"Lancet Oncol"},{"issue":"26","key":"7333_CR18","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1200\/JCO.2016.71.9815","volume":"35","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, K\u00fcemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA (2017) De-escalation strategies in human epidermal growth factor receptor 2 (HER2)\u2013positive early breast cancer (BC): final analysis of the West German Study Group adjuvant dynamic marker\u2013adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2\u2014and hormone receptor\u2013positive phase II randomized trial\u2014Efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol 35(26):3046\u20133054. https:\/\/doi.org\/10.1200\/JCO.2016.71.9815","journal-title":"J Clin Oncol"},{"key":"7333_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01816","author":"N Harbeck","year":"2023","unstructured":"Harbeck N, Nitz UA, Christgen M, K\u00fcmmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just M, zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, J\u00f3\u017awiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; the WSG-ADAPT investigators, (2023) De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+\/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP Trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01816","journal-title":"J Clin Oncol"},{"issue":"9","key":"7333_CR20","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","volume":"6","author":"I-SPY Trial Consortium; Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van\u2019t Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA","year":"2020","unstructured":"I-SPY Trial Consortium; Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van\u2019t Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA (2020) Association of event-free and distant recurrence\u2013free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol 6(9):1355\u20131362. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2535","journal-title":"JAMA Oncol"},{"key":"7333_CR21","unstructured":"ClinicalTrials.gov (2020) A study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive participants with residual invasive breast cancer following neoadjuvant therapy (DESTINY-Breast05). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04622319 Accessed 1 Aug 2023"},{"key":"7333_CR22","unstructured":"Daiichi Sankyo (2021) DESTINY-Breast11 neoadjuvant phase 3 trial of ENHERTU initiated in patients with high-risk HER2-positive early-stage breast cancer. Business Wire https:\/\/businesswire.com\/news\/home\/20211130005319\/en\/DESTINY-Breast11-Neoadjuvant-Phase-3-Trial-of-ENHERTU\u00ae-Initiated-in-Patients-with-High-Risk-HER2-Positive-Early-Stage-Breast-Cancer Accessed 1 Aug 2023"},{"key":"7333_CR23","unstructured":"ClinicalTrials.gov (2021) Trastuzumab deruxtecan (T-DXd) with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer (DESTINY-Breast09). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04784715 Accessed 1 Aug 2023"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07333-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T06:07:15Z","timestamp":1720418835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07333-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7333"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07333-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"31 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takano T received honoraria for lectures (personal) from Chugai Pharmaceutical, Daiichi Sankyo, and Eli Lilly Japan. Masuda N received grants (to institution) from Chugai Pharmaceutical, Eli Lilly Japan, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis Pharma, Sanofi, Kyowa Kirin and Nippon Kayaku; received honoraria (personal) from Chugai Pharmaceutical, Pfizer, AstraZeneca, Eli Lilly Japan and Daiichi Sankyo; is a representative of Board of Directors (unpaid) for Japan Breast Cancer Research Group (JBCRG), and a member of Board of Directors (unpaid) for Japanese Breast Cancer Society (JBCS). Inoue K received grants (to institution) from MSD, Daiichi Sankyo, Chugai Pharmaceutical, AstraZeneca, Sanofi, Astellas, Ono Pharmaceutical, Takeda Pharmaceutical, Eisai, Gilead, and Novartis Pharma. Kawaguchi K received grants (to institution) from Terumo, Astellas, Eli Lilly Japan, Kyoto Breast Cancer Research Network (KBCRN) and Daiichi Sankyo; received consulting fees (personal) from Becton Dickinson Japan; received honoraria (personal) from Eisai, Chugai Pharmaceutical, Takeda Pharmaceutical, Daiichi Sankyo and MSD. Yasojima H received honoraria (personal) from Eisai, Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan, Daiichi Sankyo and Pfizer. Bando H received honoraria (personal) from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Eisai, Kyowa Kirin, AstraZeneca, Pfizer and MSD; is a member of Advisory Board for Chugai Pharmaceutical and Eli Lilly Japan. Nakamura R received honoraria (personal) from Eli Lilly Japan, AstraZeneca, Daiichi Sankyo and Chugai Pharmaceutical. Yamanaka T received honoraria for lectures (personal) from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Kyowa Kirin, Novartis Pharma, Pfizer and Taiho Pharmaceutical. Aruga T received honoraria (personal) from Pfizer, Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan and Kyowa Kirin. Tokunaga E received honoraria (personal) from Eli Lilly Japan, Daiichi Sankyo and AstraZeneca. Aogi K received grants (to institution) from Chugai Pharmaceutical, Eisai and Takeda Pharmaceutical; received honoraria (personal) from Eisai, Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Daiichi Sankyo and Pfizer. Ohno S received honoraria (personal) from Chugai Pharmaceutical, MSD, Eli Lilly Japan and Nippon Kayaku. Morita S received honoraria (personal) from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, MSD, Pfizer, Taiho Pharmaceutical, Novartis Pharma. Toi M received grants (to institution) from Kansai Med Net, AFI technology, Eisai, Astellas, Nippon Kayaku, Taiho Pharmaceutical, Sanwa Syurui, Shimadzu, Chugai Pharmaceutical, Pfizer, Yakult, Zene, AstraZeneca, and JBCRG; received consulting fees (personal) for Advisory Board from Bertis, Eli Lilly Japan and Daiichi Sankyo; received honoraria for chair (personal) from AstraZeneca, MSD, Eisai, Devicor Medical Japan, Kyowa Kirin, Daiichi Sankyo, Eli Lilly Japan, Nippon Kayaku, Taiho Pharmaceutical, Exact Science, Shimadzu, Chugai Pharmaceutical, Pfizer, Yakult and Sysmex; is a chairman (unpaid) of JBCS, a member of Board of Directors (unpaid) for JBCRG and KBCRN, and an associate editor of Breast Cancer Research and Treatment, Science Reports and Cancer Science. Ito M, Tanabe Y, Ishida K, Yanagita Y, Kasai H, and Kataoka TR have nothing to declare associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki and relevant ethical guidelines for clinical and epidemiological studies. Furthermore, approval from an ethics committee was obtained at each institution at the start of both the Neo-peaks study and the present follow-up study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to participate in the Neo-peaks study was obtained from all patients at the time of enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}